NASDAQ:NRIX

Nurix Therapeutics (NRIX) Stock Forecast, Price & News

$7.86

-0.28 (-3.44%)

(As of 09/29/2023 ET)

Compare

Today's Range: $7.78
▼
$8.31
50-Day Range: $7.86
▼
$9.74
52-Week Range: $7.78
▼
$15.09

Volume: 288,274 shs
Average Volume: 388,230 shs
Market Capitalization: $378.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.44

Nurix Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 249.2% Upside
$27.44 Price Target
Short Interest: Bearish
14.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.24
Based on 2 Articles This Week
Insider Trading: Selling Shares
$43,898 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.55) to ($3.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

796th out of 972 stocks

Pharmaceutical Preparations Industry

378th out of 449 stocks

3.4

Analyst's Opinion

Consensus Rating
Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.44, Nurix Therapeutics has a forecasted upside of 249.2% from its current price of $7.86.
Amount of Analyst Coverage
Nurix Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
14.32% of the float of Nurix Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Nurix Therapeutics has a short interest ratio ("days to cover") of 20.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Nurix Therapeutics has recently increased by 12.54%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nurix Therapeutics does not currently pay a dividend.
Dividend Growth
Nurix Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NRIX.

3.5

News and Social Media Coverage

News Sentiment
Nurix Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Nurix Therapeutics this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
MarketBeat Follows
2 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,898.00 in company stock.
Percentage Held by Insiders
Only 7.20% of the stock of Nurix Therapeutics is held by insiders.
Percentage Held by Institutions
90.36% of the stock of Nurix Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.55) to ($3.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nurix Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nurix Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nurix Therapeutics has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Price History

30 days | 90 days | 365 days | Advanced Chart

NRIX Stock News Headlines

September 28, 2023 | finance.yahoo.com

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

September 20, 2023 | finance.yahoo.com

Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for Investors

October 1, 2023 | Goldco (Ad)

Biden's Digital Dollar Nightmare

On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!

September 15, 2023 | finance.yahoo.com

Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a Bet

September 15, 2023 | finance.yahoo.com

Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know

September 8, 2023 | finance.yahoo.com

Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?

September 7, 2023 | msn.com

Needham Reiterates Nurix Therapeutics (NRIX) Buy Recommendation

September 7, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Nurix Therapeutics

October 1, 2023 | Goldco (Ad)

Biden's Digital Dollar Nightmare

September 7, 2023 | marketwatch.com

Nurix Therapeutics Shares Rise Premarket on Seagen Collaboration >NRIX

September 7, 2023 | finance.yahoo.com

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

August 24, 2023 | finance.yahoo.com

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

August 2, 2023 | finance.yahoo.com

Insider Sell: Gwenn Hansen Sells 1,884 Shares of Nurix Therapeutics Inc

July 24, 2023 | markets.businessinsider.com

Analyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma Data

July 24, 2023 | msn.com

HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation

July 24, 2023 | finance.yahoo.com

Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade

July 18, 2023 | markets.businessinsider.com

SVB Securities Remains a Buy on Nurix Therapeutics (NRIX)

July 17, 2023 | msn.com

Morgan Stanley Maintains Nurix Therapeutics (NRIX) Equal-Weight Recommendation

July 15, 2023 | finance.yahoo.com

Nurix Therapeutics Second Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag

July 14, 2023 | finanznachrichten.de

Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

July 13, 2023 | finance.yahoo.com

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

July 11, 2023 | finance.yahoo.com

Swedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy?

June 29, 2023 | finance.yahoo.com

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

June 26, 2023 | benzinga.com

Oppenheimer Assumes Nurix Therapeutics at Outperform, Announces Price Target of $25

June 15, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX), MoonLake Immunotherapeutics (MLTX) and Zoetis (ZTS)

June 14, 2023 | finance.yahoo.com

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

May 25, 2023 | finance.yahoo.com

Nurix Therapeutics (NASDAQ:NRIX) shareholders have earned a 25% return over the last year

See More Headlines

Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRIX Company Calendar

Last Earnings: 7/13/2023
Today: 10/01/2023
Next Earnings (Estimated): 10/05/2023
Fiscal Year End: 11/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NRIX
CUSIP: N/A
CIK: 1549595
Web: www.nurixtx.com
Phone: 415-660-5320
Fax: N/A
Employees: 297
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $27.44
High Stock Price Forecast: $36.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +249.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-180,360,000.00
Net Margins: -258.37%
Pretax Margin: -258.37%
Return on Equity: -53.36%
Return on Assets: -39.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.01
Quick Ratio: 4.01

Sales & Book Value

Annual Sales: $38.63 million
Price / Sales: 9.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.44 per share
Price / Book: 1.22

Miscellaneous

Outstanding Shares: 48,200,000
Free Float: 44,730,000
Market Cap: $378.85 million
Optionable: Not Optionable
Beta: 1.63

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Arthur T. Sands M.D. (Age 61)
Ph.D., CEO, Pres & Director
Comp: $910.98k

Mr. Johannes Van Houte (Age 57)
Chief Financial Officer
Comp: $650.74k

Dr. Gwenn M. Hansen Ph.D. (Age 52)
Chief Scientific Officer
Comp: $661.19k

Dr. John Kuriyan Ph.D.
Founder & Member of Scientific Advisory Board

Dr. Michael Rapé Ph.D.
Founder & Member of Scientific Advisory Board

Dr. Arthur Weiss M.D.
Ph.D., Founder & Member of Scientific Advisory Board

Rita Kwong
Sr. Accounting Mang.

Dr. Christine Ring J.D. (Age 58)
Ph.D., Gen. Counsel & Sec.

Mr. Eric C. Schlezinger J.D. (Age 56)
Chief People Officer

Dr. Jason Kantor Ph.D.
Exec. VP of Fin. & Bus. Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NRIX Stock - Frequently Asked Questions

Should I buy or sell Nurix Therapeutics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NRIX shares.
View NRIX analyst ratings or view top-rated stocks.
What is Nurix Therapeutics' stock price forecast for 2023?: 9 brokerages have issued 1-year price objectives for Nurix Therapeutics' shares. Their NRIX share price forecasts range from $11.00 to $36.00. On average, they predict the company's share price to reach $27.44 in the next twelve months. This suggests a possible upside of 249.2% from the stock's current price.
View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts.
How have NRIX shares performed in 2023?: Nurix Therapeutics' stock was trading at $10.98 at the beginning of the year. Since then, NRIX shares have decreased by 28.4% and is now trading at $7.86.
View the best growth stocks for 2023 here.
When is Nurix Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 5th 2023.
View our NRIX earnings forecast.
How were Nurix Therapeutics' earnings last quarter?: Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its earnings results on Thursday, July, 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. The company had revenue of $30.68 million for the quarter, compared to analyst estimates of $21.96 million. Nurix Therapeutics had a negative net margin of 258.37% and a negative trailing twelve-month return on equity of 53.36%.
What ETF holds Nurix Therapeutics' stock ?: ARK Genomic Revolution ETF holds 2,333,922 shares of NRIX stock, representing 0.94% of its portfolio.

What other stocks do shareholders of Nurix Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).
When did Nurix Therapeutics IPO?: (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.
What is Nurix Therapeutics' stock symbol?: Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX."
How do I buy shares of Nurix Therapeutics?: Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nurix Therapeutics' stock price today?: One share of NRIX stock can currently be purchased for approximately $7.86.
How much money does Nurix Therapeutics make?: Nurix Therapeutics (NASDAQ:NRIX) has a market capitalization of $378.85 million and generates $38.63 million in revenue each year. The company earns $-180,360,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.
How many employees does Nurix Therapeutics have?: The company employs 297 workers across the globe.
How can I contact Nurix Therapeutics?: The official website for the company is www.nurixtx.com. The company can be reached via phone at 415-660-5320 or via email at wolffe@wheelhouselsa.com.

This page (NASDAQ:NRIX) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial